Login / Signup

Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma.

Yusuke MatobaDominique T ZarrellaVenkatesh PooladandaMaryam Azimi MohammadabadiEugene KimShaan KumarMengyao XuXingping QinLauren J RayKyle M DevinsRaj KumarArtem KononenkoEric EisenhauerIrva E VeillardWataru YamagamiSarah J HillKristopher A SarosiekOladapo O YekuDavid R SpriggsBo R Rueda
Published in: British journal of cancer (2024)
These findings suggest inhibiting Gal3 may benefit USC patients.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • high grade
  • peritoneal dialysis
  • prognostic factors
  • signaling pathway
  • cancer therapy
  • patient reported outcomes
  • drug delivery